Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.

Conclusion: The refractory MG patients are most commonly female with an early age of onset, anti-MuSK antibodies, and thymomas. Refractory MG patients have higher prevalence and poor control (HbA1C >8%) of diabetes mellitus and dyslipidemia probably due to increased steroid usage. Rituximab is very efficient in treatment of refractory MG with adverse effects being low.
PMID: 27790079 [PubMed - in process]

Source: GMS German Medical Science - October 31, 2016 Category: Journals (General) Tags: Ger Med Sci Source Type: research